FITEC, managed by Fondo Italiano d’Investimento, completes the second exit with the sale of Healthware to US-based EVERSANA

Since the Fund’s investment in 2019, the company doubled its revenues and made 4 acquisitions

Milan, October 12th, 2023 – Fondo Italiano d’Investimento SGR announces the sale of Healthware, a company in the portfolio of the FITEC Fund, dedicated to growth capital for high-growth tech companies.

The acquisition, announced yesterday, was carried out by US-based EVERSANA, among the leading global service providers for the life science industry.

Healthware, is an integrated consulting group that offers large companies and startups in the life sciences and insurance sectors a unique set of services and expertise. The group was founded 25 years ago by entrepreneur Roberto Ascione and in 2019 saw the investment of FITEC, in order to grow and further internationalize the company. Since then, Healthware has doubled its net sales and carried out four acquisitions, expanding its business to more than 10 countries, with 150 people and new offices, in London and Helsinki, in addition to its headquarters in Salerno and offices in Milan and Rome.

This is the second successful exit completed by FITEC, following SECO, a company that was listed with FITEC’s contribution on the Euronext STAR Milan segment.

The digital health and digital therapeutics business of the Healthware Group was spun out, the FITEC fund and the entrepreneur will continue managing them.

Mauro Pretolani, Senior Partner of Fondo Italiano d’Investimento said:

“We are satisfied with the results obtained by Healthware thanks to an enlightened entrepreneur such as Roberto Ascione. The results achieved by the company in these four years and the strategic acquisition made by a group like EVERSANA confirm the strength of the company and the commitment of the FITEC team, that aims at strengthening the competitive positioning of Italian companies with high technological content like Healthware.”

Roberto Ascione, founder of Healthware, added:

“I believe this transaction is significant for several reasons: it shows on the one hand that it is possible to build scalable companies from Italy, combining growth capital with an international M&A strategy, and on the other hand that it is possible to cultivate a winning team and create an international corporate culture even starting from the South of the country. This first exit of Healthware, also testifies to the possibility of creating value in digital health and digital transformation and services to the pharmaceutical industry, areas in which we will continue to invest in this new phase of development with EVERSANA.”

Throughout the transaction, Healthware was assisted by AlTi Global, in the person of Managing Director Federico Lonoce, as financial advisor and by Orrick, with attorney Alessandro Vittoria, as legal advisor.

Read press release

ITA_CS_12.10.23_exit-Healthware_ENG_vf

Fondo Italiano d’Investimento SGR

Founded in 2010 at the initiative of the Ministry of Economy and Finance (MEF) and participated by CDP Equity, Intesa Sanpaolo, UniCredit, ENPAM Foundation, ENPAIA Foundation, ABI, Banco BPM, and BPER Banca, Fondo Italiano d’Investimento SGR's main objective is to manage closed-end mutual funds aimed at channelling capital towards the system of excellent Italian companies, combining the goal of return on invested capital in line with international benchmarks with that of fostering the growth of the Italian productive system. Fondo Italiano manages 21 closed-end mutual funds reserved for qualified investors, totalling over Euro 4 billion of capital under management, and operates through direct and indirect investments (fund of funds). Fondo Italiano considers sustainability a fundamental value and is committed to integrating environmental, social, and governance (ESG) criteria into its investment activities.

For further information

Roberto Travaglino

Fondo Italiano d’Investimento SGR

+39 02 63532 208

roberto.travaglino@fondoitaliano.it

Thanai Bernardini

External press office

+39 335 7245418

me@thanai.it

Alessandro Bozzi Valenti

External press office

+39 348 0090866

alessandro.valenti@thanai.it